Nash Fibrosis
FASCINATE-2 topline data: Denifanstat surpasses placebo for NASH with fibrosis at week 52
Topline data from the phase 2b FASCINATE-2 trial showed “statistically significant improvement” for denifanstat in biopsy-confirmed nonalcoholic steatohepatitis with stage 2 or stage 3 fibrosis at 52 weeks, Sagimet Biosciences announced.
Hepatologists, gastroenterologists lead NASH diagnosis yet ‘underdiagnosis’ persists
Gastroenterologists and hepatologists were leaders in nonalcoholic steatohepatitis diagnosis and viewed as primary coordinators of care, but the condition is still underdiagnosed and undertreated overall, noted data in BMC Gastroenterology.
Top in GI: Outpatient appendicitis management; promising treatment candidate for NASH
A recent study showed that outpatient antibiotic management was safe compared with in-hospital care for patients with acute appendicitis.
Fatigue linked to worse clinical prognosis, quality of life in patients with NAFLD
LONDON — Lower fatigue scores at baseline correlated with adverse clinical events among patients with advanced nonalcoholic steatohepatitis, according to research presented at the International Liver Congress.
Resmetirom ‘has potential to be first medication approved’ for patients with NASH
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.
Circulating micro-RNA diagnoses NASH in patients with NAFLD
Combined serum circulating micro-RNA served as a novel biomarker for the diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease, according to research published in Nature Scientific Reports.